Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53^rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.

Accepted abstracts include:

Abstract #: 252
Abstract title: Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial
First author: Max Topp, MD, University of Wuerzburg, Wuerzburg, Germany
Presentation date and time: Monday, December 12, 8:15 AM ET
Location: San Diego Convention Center, Room 29

Abstract #: 1637
Abstract title: Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma
First author: Andreas Viardot, MD, University Hospital Ulm, Ulm, Germany
Presentation date and time: Saturday, December 10, 5:30 PM - 7:30 PM
Location: San Diego Convention Center, Hall GH